Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02647866 · ClinicalTrials.gov registry record · Phase 2
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
A Phase 2 study, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT02647866 is a Phase 2 study that has completed, run by Kyowa Kirin. The registered enrollment target is 66 participants.
The verdict
NCT02647866, a Phase 2 study, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC) followed by a Long-term Extension Therapy (LTE) phase for eligible subjects with a clinical response.
Interventions
- DRUG Placebo
- DRUG KHK4083
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02647866
The ClinicalTrials.gov registry entry for NCT02647866 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02647866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02647866 about?
NCT02647866 is a clinical study titled "Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis". The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC) followed by a Long-term Extension Therapy (LTE) phase for eligible subjec...
What is the current status of trial NCT02647866?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2016-06. Estimated completion is 2018-10.
What interventions are being tested in trial NCT02647866?
The interventions under investigation include: Placebo (DRUG), KHK4083 (DRUG).
Who is sponsoring clinical trial NCT02647866?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.